GPCR
Structure Therapeutics Inc.
NASDAQ · USHealthcareBiotechnology
$46.98-3.09%
Price as of Jul 20, 2026
GPCR financials
Structure Therapeutics Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $3.9M | $0.00 | $0.00 | $0.00 |
| Gross profit | -$3.9M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $283.7M | $158.2M | $102.8M | $52.6M |
| Operating income | -$287.6M | -$158.2M | -$102.8M | -$52.6M |
| Net income | -$141.2M | -$122.5M | -$89.6M | -$51.3M |
| EBITDA | -$136.8M | -$121.2M | -$75.7M | -$51.0M |
| Basic EPS | $-2.40 | $-2.34 | $-2.43 | $-1.44 |
| Diluted EPS | $-2.40 | $-2.34 | $-2.43 | $-1.44 |
| Balance sheet | ||||
| Cash & equivalents | $799.6M | $169.5M | $129.8M | $26.1M |
| Total assets | $1.6B | $903.3M | $482.0M | $97.8M |
| Total liabilities | $67.5M | $38.5M | $29.1M | $213.0M |
| Stockholders’ equity | $1.5B | $864.8M | $453.0M | -$115.1M |
| Total debt | $6.5M | $3.9M | $5.5M | $260.0K |
| Net debt | -$793.1M | -$165.6M | -$124.3M | -$25.8M |
| Cash flow | ||||
| Operating cash flow | -$222.2M | -$116.6M | -$79.5M | -$46.1M |
| Capital expenditure | -$3.6M | -$1.3M | -$2.2M | -$155.0K |
| Free cash flow | -$225.8M | -$117.9M | -$81.7M | -$46.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |